期刊
CLINICA CHIMICA ACTA
卷 440, 期 -, 页码 36-39出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2014.11.002
关键词
L-Arginine Asymmetric Dimethyl; Nitric oxide; Renal disease; Cardiovascular disease
资金
- FAPEMIG [CDS APQ-3535-4.04]
- CNPq/Brazil [480637/2013-0]
- CNPq Research Fellowship [302794/2012-3]
Background: Asymmetric Dimethylarginine (ADMA) is a modified amino acid formed when intracellular arginine is methylated by methyltransferases that are widely distributed throughout the body. Nitric oxide (NO) is produced from L-arginine in a reaction catalyzed by three distinct isoforms of NO synthase (NOS). NO has emerged as a mediator involved in maintenance of vascular tonus, blood pressure regulation, inhibition of platelet aggregation, leukocyte and endothelial cell interaction and vascular permeability. ADMA is an important inhibitor that competes with NOS and compromises NO synthesis. Objective: This review aims to compile articles involving renal and cardiovascular diseases in which plasma ADMA was assessed in order to clarify its role in these diseases. Conclusion: Although current knowledge suggests that ADMA has a role in the onset of cardiovascular and renal diseases, its actions are poorly understood. Clarifying its biochemical mechanisms is essential for improving disease management and promoting better quality of life for these patients. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据